SCHOTT PHARMA AG & CO. KGAA
SCHOTT PHARMA AG & CO. KGAA/ DE000A3ENQ51 /
1SXP
|
03/09/2024 15:30:42
|
Chg.
-0.70
|
Volume |
Bid17:08:00 |
Demandez à17:08:00 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
34.74EUR
|
-1.98%
|
0
Chiffrre d'affaires: - |
34.50Bid taille: 258 |
34.56Ask la taille: 258 |
5.2 Mrd.EUR |
0.43% |
34.16 |
Description de l'entreprise
For more than 100 years, the SCHOTT name has represented advanced solutions and services for the global pharmaceutical and biotech industries. With this longstanding expertise, SCHOTT Pharma provides an extensive and scientifically proven product portfolio for the safe storage and administration of injectable drugs to patients all over the world.
SCHOTT Pharma`s portfolio ranges from prefillable syringes, cartridges, vials, and ampoules to analytical, development, fill-and-finish, and regulatory services for pharmaceutical companies, biotechs, and CDMOs.
Conseil d'administration & Conseil de surveillance
| PDG |
| - |
| Conseil d'administration |
| Andreas Reisse, Dr. Almuth Steinkuhler |
| Conseil de surveillance |
| Peter Goldschmidt, Dr. Wolfgang Wienand, Ann-Kristin Erkens , Eva Kienle, Christine Wening, Mario Just, Dr. Jorg Flatten, Thomas Schoning, Oliver Spika, Kai Olbricht |
Données de l'entreprise
| Nom: |
SCHOTT PHARMA INH O.N. |
| Adresse: |
Hattenbergstrasse 10,Mainz, 55122 |
| Téléphone: |
- |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
https://www.schott-pharma.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Medical Products |
| Sous-secteur: |
Medical Supplies |
| Fin de l'exercice financier: |
30/09 |
| Flotte libre: |
23.00% |
| IPO date: |
28/09/2023 |
Relations avec les investisseurs
| Nom: |
Jasko Terzic |
| Téléphone IR: |
- |
| IR-Fax: |
- |
| E-mail IR: |
IR.Pharma@schott.com
|
Calendrier de l'entreprise
|
CW 50 | 12/12/2024
Annual Report
|
|
CW 6 | 04/02/2025
General Shareholder Meeting
|
|
CW 7 | 13/02/2025
Interim Report 1st Quarter/3 Months
|
|
CW 20 | 15/05/2025
Interim Report 2nd Quarter/6 Months
|
|
CW 33 | 12/08/2025
Interim Report 3rd Quarter/9 Months
|
